ARTICLE BY Cam Duffy for the Australian Psychedelic Society.
Originally presented at the 2017 Melbourne Bicycle Day event.
In 1938 Albert Hoffman, who had earlier isolated and discovered the psychoactive effects of LSD, became the first person in history to purposefully ingest the substance, all 250 mcg of it. After establishing that he was physically stable and having a nonetheless intense psychological experience, Hoffman realized that the substance could be utilized for its psychological effects.
Sandoz laboratories began marketing and distributing the substance to researchers and psychiatrists around the world. What resulted was an interesting period in the history of psychiatry, one in which psychiatrists were encouraged to explore the novel domains of the unconscious in a similar manner to the efforts of modern day psychonauts.
In the early to mid-1950s, LSD experimentation in mental health settings became particularly interesting.
The term ‘psychedelic’ was first used in 1956 by Canadian psychiatrist and LSD researcher Dr Humphrey Osmond. It translates as “mind manifesting”.
Dr Osmond collaborated with notable historical figures that include English novelist and writer of the highly influential book about the significance of the psychedelic experience ‘The Doors of Perception, Heaven & Hell’, Aldous Huxley, as well as government officer and scientific reader, Al Hubbard. Like Huxley, Hubbard became highly interested in the effects of LSD and he reportedly introduced more than 6,000 people to it in total, including scientists, politicians, intelligence officials, diplomats, and church figures.
The military began experimenting with LSD, and the CIA in the U.S. had started to explore its potential utility as a tool for psychological warfare and manipulation. The result was a considerable period of research and infamous projects such as ‘MK-ULTRA’.
Ken Kesey of ‘Merry Pranksters’ fame was a notable volunteer for one MK-ULTRA study:
LSD became utilized for its apparent ability to reform alcoholics and treat a variety of mental health conditions. Clinics all over the U.S., the UK and Europe, were involved in researching the efficacy of LSD for improvement in mental health symptoms. In the UK, 683 patients were treated with LSD in over 13, 785 separate sessions. In one study conducted under the supervision of aforementioned Canadian, Dr Humphrey Osmond, a year after their supervised LSD experience, almost 50% of the study group had not consumed alcohol, a result that 21st century clinics would consider difficult to achieve with a combination of pharmacotherapy and counselling.
Co-founder of ‘Alcoholics Anonymous’, Bill Wilson, tried LSD with the assistance of Dr Sidney Cohan and British-born American intellectual, writer, and mentor Gerald Heard. He was said to have felt that it helped him to eliminate many barriers erected by the self/ego that stand in the way of one’s direct experience of the “cosmos and of god”.
Gerald Heard himself referred to the LSD experience as unique in its inspirational value, see:
Psychiatrist and contributor to the development of modern transpersonal psychology, Dr Stanislav Grof, realized that the scope of potential experience when under the influence of LSD involved the transcendence of ordinary boundaries and ideas about the nature of consciousness.
This came after making the following observation during his first experience with LSD in 1956 in which a stroboscopic light was the additional applied stimulus during a research experiment (scroll down to first mentioning of “Grof”).
Grof has described psychedelics like LSD in his books as ‘non-specific amplifiers of consciousness’.
In late 1961, infamous Harvard personality psychologist, Dr Timothy Leary, who had been involved in setting up the ‘Harvard Psilocybin Project’ along with Dr Richard Alpert (now known as ‘Ram Dass’) and Dr Ralph Metzner, first tried LSD. Leary had previously been unmotivated to try LSD having already experienced profound effects from a psilocybin mushroom experience, considering it redundant to try another seemingly generic stimulus. Five years after his first LSD experience, Leary described the impact it had on him on page 256 of his book ‘High Priest’:
This was is an understandable precursor to the subsequent change in Leary’s behaviour that eventually led to him being labelled, hyperbolically, as “the most dangerous man in America” by later impeached president and notable establisher of the “War on Drugs”, Richard Nixon.
At Harvard, the three psychologists became fascinated by the insights and personality transforming tendencies of LSD. So impressed by its effects, widespread use amongst the researchers and their friends in the academic, artistic, and socialite community commenced.
After the period of dissonance with the scientific community and university officials that resulted, Leary went rogue and began to promote the mainstream use of LSD, becoming a political figure in this regard. What resulted largely from Leary’s promotion was an almost unprecedented social movement the momentous effects of which are still realized to this day.
Art, music, technology, fashion, sexuality, and social identity became revolutionized through the widespread use of LSD in the 1960s, though political backlash and paranoia led to media coverage that highlighted generally rare instances of LSD causalities.
The importance of mindset and physical setting as contributing factors to the experience eventually became a tough lesson for promoter, Leary, and many less educated users of LSD. LSD use was common amongst Vietnam war protesters, part of Nixon’s initial motivation for the “War on Drugs”.
However, there is no dusk without a dawn, thanks to the efforts of the Multi-Disciplinary Association for Psychedelic Studies led by Dr Rick Doblin, psychiatrist Dr Rick Strassman in the 1990s, as well as select European research groups, psychedelic therapy and research has been kick-stated in recent years. This may be likened to a new renaissance of discovery regarding the utility of LSD and other psychedelics, making use of new technologies and carefully designed scientific protocols. Albert Hoffman’s “problem child” is being rediscovered as the “wonder drug” of the past.
Despite the challenge of government or institutional barriers, as long as we respect the power of mind set and physical setting variables, the future of research and potential applications of LSD is vibrant and open to whatever our innovative tendencies may make of it.
The APS’ Dean Wright with Annie and Michael Mithoefer
Today I was told exactly how to conduct the sessions to treat post-traumatic stress disorder, using MDMA-assisted psychotherapy. We sat in the conference centre at the Marriot Hotel in Oakland, California, as part of the world’s largest conference about psychedelics – Psychedelic Science 2017.
The seminar was conducted by Annie and Michael Mithoefer, a husband and wife duo who conducted the MDMA-assisted psychotherapy sessions in the MAPS studies. The Mithoefer’s literally wrote the manual on how to conduct psychotherapy using MDMA.
This therapy involves four stages: introductory sessions, preparatory sessions, the MDMA-therapeutic session and integration sessions.
In the introductory session, the aim is to establish trust and rapport with the patient. This involves being completely transparent about what the patient can expect from the sessions, and how they will be conducted. The therapist encourages the client to ask any questions and bring forth any worries they have about the process, so any anxieties can be addressed and put to rest prior to the therapy. The therapist then lays the ground rules around what is required of the client – including time requirements and behavioural boundaries.
This is the beginning of the therapy, where therapists begin to understand the nature of the trauma and its presentation. During these sessions the therapist seeks to understand what the traumatic events are, what are the triggers that remind the client of the trauma, and how does the trauma affect their everyday life. Very often these patients will have concomitant depression; will suffer from nightmares, constant anxiety and panic attacks. After learning as much about the patient’s particular experience of PTSD, and after the patient feels as though they know exactly how the sessions will be conducted, they proceed to the MDMA-assisted session.
The session is conducted in a comfortable environment. The patient lays on a bed, a male and female therapist sit either side. An 8-hour playlist of music is played, and after ingesting the MDMA, the patient is invited to lay down with eye-shades and headphones on. When the patient feels the need to discuss or disclose information, they are invited to do so.
Both male and female therapists are used to provide balance, as very often during these sessions, the patient will undergo some transference. Transference is when the patient transfers some parts of their personal relationships onto the therapists. For example, if their mother was caring and their father did not show love, then they may feel more comfortable to disclose information to the female therapist and show resistance with the male therapist. In this context, as healing occurs you might see the patient begin to open up to the male therapist, and actually convey some of their painful feelings. This transference is an essential part of the therapeutic relationship.
The therapists communicate in a non-directive manner. This means they do not force the patient to think about their trauma and they do not decide if a topic brought up by the patient is important or not. That is because when people take MDMA, they will often bring up events which they previously have not remembered or considered important. In reality, these events may have shaped their current state and may be important – MDMA is a great tool for bringing to the surface the issues which are important.
This non-directive approach involves active listening, empathy and compassion. This involves reflecting what the patient is going through. Acknowledging how difficult it might be, and normalising and difficult feelings they might be having. It may involve soothing the patient during difficult times with physical touch such as a hug or stroking the patient’s hair. To treat PTSD it is important not to tell the patient how to think better, but just to allow the patient the space to relive the trauma.
MDMA is such a great tool for treating PTSD as it allows the patient to relive the trauma without being overwhelmed by difficult feelings. Normally when a person with PTSD recalls a traumatic event, they become overwhelmed with anxiety and pain that all they can do is think of ways to escape the pain and stop thinking of the trauma. By being able to relive all the trauma in the context of MDMA, they no longer feel the overwhelming anxiety anymore. Eventually with integration they will be able to recall these traumatic memories without any imposition on their function.
Integration is highly important in the therapeutic process. This is because MDMA may enable the patient to recall events which were previously inaccessible to the patient. These memories may keep coming days, weeks or months after the therapy. For this reason the patient needs a lot of aftercare, with access to a therapist to talk to at all hours for several days afterwards, and with regular therapy for the coming months. These therapeutic sessions will continue until the patient no longer brings up new memories, and these memories no longer cause dysfunctional feelings in the patient. The patient may need to undergo several more rounds of MDMA and integration therapies. However, the time invested is well worth it, particularly since these patients were previously considered untreatable, and had to live this debilitating existence for the rest of their life. With MDMA therapy 70-80% of patients no longer suffer from PTSD (Mithoefer et al, 2010).
By Melissa Warner and Dean Wright, PhD
The last few weeks have seen magic mushrooms and their potential to treat depression spotlighted in the media.
This is just another of the latest installments highlighting the changing perception of the media (and the public) on the valid use of psychedelic substances.
The study that birthed these news-bites was conducted at the Imperial College London, in the labs of the esteemed psychedelic scientist, David Nutt and was led by his protégé; Robin Carhart-Harris. This is the same team that brought you the equally publicised cardinal LSD imaging study earlier this year.
The study is titled “Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study” and was published in The Lancet Psychiatry, one of the most revered journals in psychiatry.
Over recent years, more and more psychedelic studies are being published in high-impact journals. The esteem of the journal can imply two things to a reader:
1) The findings of the study are novel and exciting.
2) The wider scientific community is starting to accept the use of psychedelic drugs as medicines
About time right?
So where do mushrooms fit on the societal landscape?
Magic Mushrooms – Public Policy and Other Dissociated Realities
Although it may seem irrational to ban a naturally occurring substance, magic mushrooms, and the active ingredient psilocybin, are recognised as a Schedule 1 substance as soon as they are picked from the earth.
Schedule 1 is home to substances that: 1) have a high potential for abuse, 2) are unsafe and 3) have no medical use.
The growing and established scientific evidence does not support the scheduling of psilocybin into this category.
Not only does psilocybin hold no potential for abuse or addiction, rather if you input the search terms ‘psilocybin’ and ‘addiction’ into a journal database, what you are likely to find are a range of pilot studies and reviews like this, and this, describing the therapeutic potential of psilocybin in treating addiction.
We failed to find any scientific evidence of harms from psilocybin when used in a safe setting. In fact, a recent study has shown that use of psilocybin is associated with reduced risk of suicide. This may be because psilocybin is able to increase positive moods, whilst stimulating spiritual experiences.
In fact a study at Jon Hopkins has shown the magnitude of a spiritual experience on psilocybin to be directly proportional to the efficacy and duration of therapeutic effect.
Suggesting that the therapeutic effect is embedded within the psychedelic experience
The range of potential medical range from not only addiction, but also in alleviating near death anxiety, the treatment of autism and now, as described in this study, to alleviate treatment-resistant depression.
None of this coming as any surprise to experienced psychonauts.
As always, even when the media gets it right the results are distilled with that thrilling ring of hyperbole.
This particular study has spurred many mainstream media articles to publish about this study, describing how “magic mushrooms beat severe depression”.
They go on to describe how 12 patients were given magic mushrooms.
With all 12 participants showing reductions in depression after 1 week!
With “the majority still showing effects after 3 months”.
However, even as psychonauts who have experienced the anxiolytic, mood enhancing effects of psilocybin we cannot allow ourselves to succumb to the all too easy pitfall of positive bias.
We have to be careful of the hype and learn to interpret the findings for what they are.
Participants of the study show a drop in depression measured after 1 week from a single therapeutic session under the influence of a strong dose of psilocybin (25mg; see figure below taken from Carhart-Harris et al, 2016).
However, do not mistake this for clinical significance, with 8 of the 12 participants in remission after one week.
This is still a great result, considering classic antidepressants (SSRIs, eg. Zoloft, Prozac) take 2-3 weeks to exhibit therapeutic effects.
Furthermore, these effects were seen in treatment-resistant patients, meaning they showed no response to at least 2 different prior treatments.
After 3 months, 5 of the 12 participants were in remission. This is approximately equal to the effect SSRIs being used daily over the same time period.
Psilocybin exerted its therapeutic effects from a single dose. In contrast, SSRIs are prescribed for a minimum of 3-6 months and very often for years, if not decades.
Additionally, SSRIs are known to cause many undesirable side-effects.
Figure 1. Levels of depression over time. All participants show a drop in depression one week after being treated with psilocybin, with 8 out of 12 in remission. Three months after a single dose of psilocybin, 5 of 12 participants remain in remission.
We have to be careful of positive bias when talking about psychedelics… actually, any science.
Not all articles present an overly optimistic picture, such as this article from vice, because it notes the limitations of the study as well as the realistic positive effects. This is something i have noticed many other reports have left out of their assessment. I think to gain acceptance and respect from the wider community, we have to be honest about the results. Some limitations of the current study include:
1) Sample size – There are only 12 participants. This is not enough to determine if the therapeutic effect of psilocybin is likely to be “real”. Hence, why the study is categorised as a “proof-of-concept” trial.
2) Selection bias – Only one participant had not previously used psilocybin to treat their depression. Furthermore, most participants were self-referred. This indicates they had a belief that psilocybin was likely to be beneficial, either due to previous experience, or due to expectation. Previous positive experience with psilocybin is likely to lead to a positive selection bias of psilocybin, because people who did not have success with self-treatment are unlikely to volunteer to be in the study. Furthermore, those who seek to participate are likely to have some expectation of the effect of psilocybin, leading to a stronger placebo effect.
3) Placebo effects – There was no control group, and given psilocybin has such a noticeable effect on perception and cognition, this is likely to create a large placebo effect.
What does this mean?
Given this study is so small and the effects may be attributed to placebo or selection bias, we can not conclude on the clinical significance of psilocybin for treating depression. However, the strength of the effect after only one week is quite striking, and if these effects were to be real they could revolutionise the treatment of depression. Thus, this “proof-of-concept” trial is successful in providing a rationale for a larger, double-blind, randomized, placebo-controlled study. We are quietly excited about the results, but are yet to hold judgment on the use of psilocybin as an antidepressant.